Table 4.
Comparison of anthropometric and glucose metabolic markers between the balloon elimination and persistence groups.
| Elimination (n = 13) | Persistence (n = 7) | ||||
|---|---|---|---|---|---|
| Median | Rage | Median | Rage | ||
| Age | 43 (21–65) | 58 (21–64) | |||
| SEX(F:M) | (6:7) | (6:1) | |||
| Follow-up duration | 6M (7), 1y (2), 2y (3), 3y (1) | 6M (5), 1y (1), 2y (1) | |||
| Ballooning grade at first biopsy | 1(9), 2(4) | 1(2), 2(5) | |||
| Baseline | |||||
| BW | 118.6 | (81.4–159.2) | 88.0 | (67.2–109.6) | |
| AUC_BS (min*mg/dL) | 18,240.0 | (13,275.0–31,455.0) | 29,475.0 | (20,685.0–39,930.0) | p = 0.0258 |
| AUC_IRI (min*ng/mL) | 9712.0 | (3390.0–21,091.5) | 9336.0 | (6202.5–27,156.0) | |
| HOMA-b | 139.4 | (32.4–421.7) | 116.0 | (83.8–298.4) | |
| HOMA-IR | 3.104 | (0.952–6.480) | 7.856 | (2.836–9.979) | p = 0.0021 |
| BS (mg/dL) | 87 | (77–142) | 119 | (99–167) | p = 0.0139 |
| IRI (ng/mL) | 12.7 | (4.7–24.6) | 23.4 | (11.6–31.5) | p = 0.0475 |
| Adiponectin | 1.83 | (0.94–5.64) | 1.33 | (0.49–2.37) | |
| SAT (cm2) | 547.1 | (255.3–743.6) | 550.4 | (436.8–629.2) | |
| VAT (cm2) | 272.0 | (132.6–385.3) | 235.0 | (127.9–311.3) | |
| Post operation | |||||
| BW (kg) | 83.0 | (60.5–117.8) | 79.0 | (67.2–93.5) | |
| Reduction of BW (kg) | 21.8 | (12.8–51.3) | 14.6 | (4.8–20.5) | p = 0.0264 |
| AUC_BS (min*mg/dL) | 17,085.0 | (11,970.0–34,740.0) | 22,965.0 | (19,800.0–33,075.0) | p = 0.0249 |
| AUC_IRI (min*ng/mL) | 5418.0 | (3013.5–9291.0) | 8404.5 | (6453.0–55,813.5) | |
| HOMA-b | 147.0 | (19.6–265.5) | 100.8 | (59.1–193.5) | |
| HOMA-IR | 1.296 | (0.356–2.572) | 4.035 | (1.034–7.191) | p = 0.0224 |
| BS (mg/dL) | 84 | (72–121) | 103 | (91–134) | p = 0.0048 |
| IRI (ng/mL) | 7.0 | (2.0–12.4) | 13.9 | (4.6–23.3) | p = 0.0157 |
| Adiponectin (mg/mL) | 4.19 | (2.19–9.16) | 2.52 | (0.99–2.52) | p = 0.0200 |
| SAT (cm2) | 325.9 | (111.3–637.3) | 420.7 | (325.4–497.1) | |
| VAT (cm2) | 123.1 | (68.7–313.5) | 165.4 | (93.4–205.6) | |
BW body weight; AUC area under curve; BS blood sugar; IRI serum insulin; HOMA homeostasis model assessment; IR insulin resistance; BS plasma sugar; subcutaneous adipose tissue and VAT, visceral adipose tissue.